April 20, 2023 – Page 2

April 20, 2023February 23, 2024

Geneticistas Reprodutivos Reunidos em Paris Apresentam Primeiro Teste de Sequenciamento Completo do Genoma Embriões

Dr. Santiago Munné, pioneiro no diagnóstico genético pré-implantação, apresentou o novo teste na Conferência PGDIS
Além de detectar genes herdados dos pais, o novo teste de laboratório também revela novas mutações que podem levar a doenças “de novo”, como o autismo.

PARIS, April 19, 2023 (GLOBE NEWSWIRE) — O Dr. Santiago Munné, pioneiro no diagnóstico genético pré-implantação, apresentou o primeiro teste de sequenciamento completo do genoma em embriões para representantes na Preimplantation Genetic Diagnosis International Society (20ª Conferência da Sociedade Internacional de Diagnóstico Genético Pré-implantação – PGDIS), realizada esta semana em Paris.

Em seu discurso no plenário com a presença de mais de 300 especialistas, o Dr. Munné, pioneiro em genética reprodutiva internacionalmente reconhecido, apresentou dados de validação do GenomeScreen, teste desenvolvido pela equipe de pesquisa liderada por ele na empresa de biotecnologia GenEmbryomics.

“Sabemos desde que começamos a trabalhar com o diagnóstico de embriões em 1993 que a seleção de embriões seria fundamental para a gravidez, especialmente em pacientes mais velhas. Nos últimos 30 anos, nosso trabalho tem se concentrado em aprimorar a seleção genética de embriões, embora a abordagem diagnóstica definitiva – que fornece mais informações e melhores resultados – seja, sem dúvida, esta: sequenciamento completo do genoma do embrião usando apenas algumas células obtidas de uma biópsia. Este teste abre portas que não sabíamos que existiam”, disse Munné sobre o trabalho realizado na GenEmbryomics.

Conhecer o genoma é conhecer um embrião antes da transferência
O GenomeScreen é um novo e revolucionário teste de sequenciamento completo do genoma para embriões de fertilização in vitro descrito como “o teste genético mais completo de fertilização in vitro” pelas autoridades do fórum PGDIS.

O teste fornece informações altamente precisas sobre a sequência do genoma do embrião e dos pais genéticos, oferecendo às famílias os principais insights pré-implantação sobre a saúde do embrião e o prognóstico reprodutivo para a tomada decisões bem-informadas. Além disso, essas informações são inestimáveis para pessoas geradas de fertilização in vitro, pois fornecem informações sobre nutrigenômica ou orientação sobre quais medicamentos são mais geneticamente adequados para o paciente.

“Quando começamos nossa pesquisa sobre o sequenciamento de embriões, nosso objetivo era criar uma ferramenta potente e abrangente para que os médicos de fertilidade pudessem acessar dados completos para uma avaliação precisa”, disse o Dr. Nick Murphy, fundador da GenEmbryomics. “Com essa ferramenta usada com 99% de confiabilidade, sabemos que, além de fornecer informações, esse diagnóstico também aumenta substancialmente o sucesso da medicina reprodutiva”, acrescentou Murphy.

O sequenciamento de embriões aumenta o índice de sucesso da fertilização in vitro

O professor Munné, líder em genética reprodutiva de mais de 20 anos, é um importante contribuinte para seleção de embriões e o tratamento de fertilização in vitro. Com este teste, ele e sua equipe de pesquisadores solidificam o papel dos testes genéticos na medicina reprodutiva, aumentando o sucesso do tratamento.

“Os resultados apresentados na conferência são os dados de validação de um teste que irá alterar a forma como a seleção de embriões é realizada”, disse Munné. “A análise genética pré-implantação com sequenciamento completo de genoma é um passo gigantesco: entre outras coisas, informará qual embrião será implantado com sucesso, porque saberemos de antemão qual deles é verdadeiramente saudável – sem doenças herdadas dos pais ou doenças de novo, como o autismo”, conclui ele.

Sobre a GenEmbryomics
Fundada pelo Dr. Nick Murphy em 2019, a GenEmbryomics é uma empresa de biotecnologia de ponta especializada na análise genômica de embriões para determinar os candidatos mais viáveis para a implantação de fertilização in vitro. Seu trabalho proporcionará índices de maior sucesso nos ciclos de fertilização in vitro, graças aos seus algoritmos proprietários que oferecem uma seleção de embriões mais precisa e eficiente, com base em todo o genoma de cada embrião.

Para mais informação
Dulce Iborra Candela
+34 647942875
dulce@laembajadora.es

GlobeNewswire Distribution ID 8811736

April 20, 2023February 23, 2024

Les généticiens de la reproduction réunis à Paris présentent le tout premier test de séquençage du génome entier dans des embryons

Le Dr Santiago Munné, un pionnier du diagnostic génétique préimplantatoire, a présenté le nouveau test lors de la Conférence PGDIS
Non seulement ce nouveau test de laboratoire détectera les gènes hérités des parents, mais il révèlera également les nouvelles mutations pouvant mener à des maladies « de novo » comme l’autisme

PARIS, 20 avr. 2023 (GLOBE NEWSWIRE) — Le Dr Santiago Munné, pionnier du diagnostic génétique préimplantatoire, a présenté le premier test de séquençage du génome entier sur des embryons devant les participants à la 20e Conférence de la Société internationale de diagnostic génétique préimplantatoire (PGDIS pour Preimplantation Genetic Diagnosis International Society), organisée cette semaine à Paris.

Lors de son allocution plénière à laquelle ont assisté plus de 300 experts, le Dr Munné, un précurseur de la génétique de la reproduction de renommée internationale, a présenté des données de validation pour GenomeScreen, le test développé par l’équipe de recherche qu’il dirige dans la société de biotechnologie GenEmbryomics.

« Nous savions, depuis que nous avons commencé à travailler sur le diagnostic embryonnaire en 1993, que la sélection embryonnaire serait déterminante pour la grossesse, surtout chez les patientes plus âgées. Au cours des 30 dernières années, notre travail s’est concentré sur l’amélioration de la sélection embryonnaire génétique, même si l’approche diagnostique définitive (celle qui fournit le plus d’informations et les meilleurs résultats) sera sans aucun doute celle-ci : le séquençage du génome entier de l’embryon à l’aide de quelques cellules seulement obtenues à partir d’une biopsie. Ce test va ouvrir des portes dont nous ignorions jusqu’à l’existence », a déclaré le Dr Munné sur le travail accompli chez GenEmbryomics.

Comprendre le génome, cela signifie tout savoir sur un embryon avant le transfert
GenomeScreen est un nouveau test révolutionnaire sur le séquençage du génome entier pour les embryons issus de FIV, qui a été décrit par les autorités comme « le test génétique le plus complet dans la FIV » lors du forum PGDIS.

Le test apporte des renseignements extrêmement précis sur la séquence du génome de l’embryon et sur les parents génétiques, fournissant aux familles des informations préimplantatoires déterminantes sur la santé de l’embryon et le pronostic de reproduction pouvant éclairer leurs décisions. Par ailleurs, ces informations seront inestimables pour les personnes nées d’une FIV, car elles fourniront des données sur la nutrigénomique ou des conseils sur les médicaments les plus génétiquement adaptés au/à la patient(e).

« Au tout début de nos recherches sur le séquençage d’embryons, notre objectif était de créer un outil complet et puissant, qui pourrait doter les médecins de la fertilité de données exhaustives pour des dépistages de précision », s’est souvenu le Dr Nick Murphy, fondateur de GenEmbryomics. « Maintenant que nous avons cet outil et que nous l’utilisons avec une fiabilité de 99 %, nous avons conscience que ce diagnostic nous fournit des informations, mais améliore également considérablement le succès de la médecine de reproduction », a ajouté le Dr Murphy.

Le séquençage des embryons va augmenter les taux de réussite des FIV

Le professeur Munné, dont la carrière en tant que chef de file en génétique reproductive s’étend sur plus de 20 ans, a apporté d’énormes contributions à la sélection embryonnaire et au traitement de FIV. Avec ce test, lui et son équipe de chercheurs solidifient le rôle des tests génétiques dans la médecine de reproduction, augmentant le succès des traitements.

Selon le professeur Munné : « Les conclusions présentées lors de la conférence constituent les données de validation d’un test qui va changer la sélection embryonnaire telle que nous la connaissons ». « L’analyse génétique préimplantatoire avec séquençage du génome entier représente un pas de géant : entre autres choses, elle nous dira quels embryons s’implanteront avec succès, car nous saurons à l’avance lesquels sont vraiment en bonne santé, c’est-à-dire sans maladie héritée des parents ou sans maladie de novo, comme l’autisme », a-t-il conclu.

À propos de GenEmbryomics
Fondée par le Dr Nick Murphy en 2019, GenEmbryomics est une société de biotechnologie de pointe spécialisée dans l’analyse génomique des embryons afin de déterminer les candidats les plus viables pour une implantation par FIV. Son travail conduira à des taux de réussite plus élevés dans les cycles de FIV, grâce à ses algorithmes propriétaires qui permettent une sélection embryonnaire plus précise et plus efficace, basée sur le génome entier de chaque embryon.

Pour tout complément d'information
Dulce Iborra Candela
+34 647942875
dulce@laembajadora.es

GlobeNewswire Distribution ID 8811736

April 20, 2023February 23, 2024

ROSEN, A LEADING LAW FIRM, Encourages Fox Corporation Investors to Inquire About Class Action Investigation – FOX, FOXA

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Fox Corporation (NASDAQ: FOX, FOXA) resulting from allegations that FOX may have issued materially misleading business information to the investing public. The prospective class includes those who purchased FOX call options and/or sold put options.

SO WHAT: If you purchased FOX securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=13327 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: In the wake of the 2020 U.S. Presidential Election, Dominion Voting Systems sued FOX for defamation. Dominion’s lawsuit alleges that FOX defamed Dominion’s business by endorsing, repeating or broadcasting a series of “verifiably false yet devastating lies about Dominion.” Dominion claims that various statements that were made on FOX News, including that Dominion committed election fraud by rigging the 2020 election, that Dominion’s software and algorithms manipulated vote counts in the 2020 election, that Dominion was founded for the purpose of rigging elections, and that Dominion paid kickbacks to government officials who used its machines, were defamatory and false. Dominion seeks over $1.6 billion in damages, as well as additional punitive damages.

Beginning in February 2023, specific details emerged of internal discussions at FOX in the wake of the 2020 election, revealing that FOX’s senior leaders understood that claims to the effect that Dominion had rigged the 2020 election were false. As a consequence, FOX faces significant potential legal liability.

As a result of ongoing revelations about FOX’s legal exposure in the Dominion lawsuit, FOX’s Class A stock has declined from a closing price of $37.03 on February 17, 2023 to a closing price of $32.52 on March 15, 2023, a 12% decline. FOX’s Class B stock has declined from a closing price of $34.22 on February 17, 2023 to a closing price of $29.83 on March 15, 2023, a 12% decline.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8811734

April 20, 2023February 23, 2024

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages LivePerson, Inc. Investors to Inquire About Securities Class Action Investigation – LPSN

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of LivePerson, Inc. (NASDAQ: LPSN) resulting from allegations that LivePerson may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased LivePerson securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=13260 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On March 15, 2023, after the market closed, LivePerson issued a press release announcing its fourth quarter 2022 financial results, which included a net loss and revenue decline. LivePerson also revealed that its subsidiary, WildHealth, received a notice that Medicare was suspending reimbursement for services rendered under the Medicare demonstrate program (the “Program”) in which certain non-core services would be provided and reimbursed by Medicare. Accordingly, LivePerson stated that given the “inherent uncertainty as to the timing and amount of further reimbursement for services rendered under the Program, the Company has elected to take a reserve for revenue associated with services delivered under the Program in the fourth quarter of 2022 for which payment has not yet been collected.”

On this news, LivePerson’s stock price fell $5.64, or 57% to close at $4.13 per share on March 16, 2023, damaging investors.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

GlobeNewswire Distribution ID 8811723

April 20, 2023February 23, 2024

TSE SHAREHOLDER ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Trinseo PLC Investors to Inquire About Securities Class Action Investigation – TSE

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Trinseo PLC (NYSE: TSE) resulting from allegations that Trinseo may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Trinseo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=13711 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On March 27, 2023, The Philadelphia Inquirer published an article entitled “Bristol plant that spilled chemicals into Philly’s water supply had other mishaps over the last decade.” The article reported “a chemical plant in Bristol that authorities said caused a toxic spill, threatening Philadelphia’s drinking water, has a long history of mishaps – including at least four recent contamination incidents.” The article also stated “over the past decade, the U.S. Coast Guard twice before detected releases of acrylates [commonly used to produce glass-like acrylics] from the Bristol facility into the Delaware [River]. The EPA had separately flagged two other acrylate releases.” The article further stated that “David Salas-de la Cruz, a Rutgers University associate professor of chemistry, worked at the Bristol plant during its Rohm and Haas days. He said the number of incidents over the past decade was unusual.”

On this news, the price of Trinseo’s stock fell $1.09, or 5%, to close at $19.62 per share on March 27, 2023.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————–

Contact Information:

GlobeNewswire Distribution ID 8811633

April 20, 2023February 23, 2024

Economist to QNA: Sudanese Crises Exacerbates Economic Situation, Pressures Citizens’ lives

The ongoing conflict in Sudan between the Army and the Rapid Support Forces has exacerbated the economic situation, which already suffers multiple problems and crises, as the conflict does not just hit Sudan’s infrastructure and productivity but also hit deep in the economic capabilities of the citizens.

Although several economic reports have not been able to estimate the scale of economic losses resulting from that conflict, Associate Professor of investment risk analysis at Al al-Bayt University, Jordan, Dr. Omar Gharaibeh considered, in his remarks to Qatar News Agency , that the continuation of confrontations would lead to the depletion of Sudan’s resources on both economic and humanitarian levels in terms of direct military spending; losses in productivity, savings, and infrastructure; and tearing up the social cohesion. He indicated that these confrontations would have a direct negative impact on growth rates, which are considered relatively low, especially since they did not exceed 2% in recent years, which impedes growth and development, increases pressures on the living conditions of citizens, and increases poverty and unemployment rates.

He explained that the continuation of the current confrontations in Sudan would form a repelling environment for investors according to the economic role that says money avoids risk and always seeks a safe environment for investment and stability. He pointed out that the confrontations would negatively impact the decline in purchasing power for the Sudanese pound and accelerates the economic collapse. The Sudanese pound exchange rate is expected to decline to 600 pounds against $1, which will increase inflation, whether at the level of prices of imported goods, production factors prices, or depletion of the states reserves of foreign currencies, which will increase the deficit in the state’s trade balance, pushing the authority for more external borrowing and increase indebtedness to cover the budget deficit, but this will have a great impact on the lives of citizens.

Source: Qatar News Agency